TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza

Horizon Therapeutics plc has had the thyroid eye disease (TED) market cornered since launching Tepezza (teprotumumab) in early 2020 and establishing a fast blockbuster drug, but Viridian Therapeutics, Inc. says its VRDN-001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist, is showing better efficacy in clinical trials designed to mimic those conducted by Horizon for Tepezza. The data are early, however, and from small number of patients so Viridian will still have work to do to successfully bring a competitor to market.

Viridian unveiled six-week data on 15 August from a Phase I/II study in a cohort of eight patients who received 10mg/kg of VRDN-001, coinciding with the company's second quarter sales...